contentSlug

type

ContentSlug_ContentQuery

slug

ContentPageContentQuery

content

trendingContent

query ContentSlug_ContentQuery(
  $contentSlug: String!
  $type: [ContentType!]
) {
  ...ContentPageContentQuery_13QmVO
}

fragment CompanyDetails_Content on Content {
  __isContent: __typename
  companies {
    name
    description
    pageUrl
    id
  }
}

fragment ContentBasicInfo on Content {
  __isContent: __typename
  id
  type
  title
  lang
  companies {
    viewerIsFollowing
    id
    name
    pageUrl
  }
  tags {
    viewerIsFollowing
    id
    name
    pageUrl
  }
  ...PublishingDetails
  ...Reactions
}

fragment ContentMetadata on Content {
  __isContent: __typename
  type
  title
  lang
  pageUrl
  alternatePageUrls: translations {
    __typename
    pageUrl
    lang
  }
  imgUrl
  description
  ... on Video {
    liveTime
    videoUrl
  }
  ... on Webcast {
    liveTime
    videoUrl
  }
}

fragment ContentPageContentQuery_13QmVO on Query {
  content(slug: $contentSlug, type: $type) {
    __typename
    id
    type
    title
    isPremium
    lang
    htmlBody
    summary
    companies {
      forum {
        latestPosts {
          ...ForumPosts
        }
      }
      name
      id
      viewerIsFollowing
      pageUrl
      defaultInstrument {
        isin
        id
        marketOpen
        marketClose
        marketplace {
          region
        }
        returns {
          total
        }
      }
    }
    tags {
      viewerIsFollowing
      id
      name
      pageUrl
    }
    createdAt
    ... on Video {
      liveTime
    }
    ... on Webcast {
      liveTime
    }
    slug
    ... on CompanyReport {
      reportUrl
    }
    ... on ThirdPartyCompanyReport {
      reportUrl
    }
    ... on StockExchangeRelease {
      reportUrl
    }
    ...ContentBasicInfo
    ...ContentMetadata
    ...PriceAndRecommendation_Content
    ...CompanyDetails_Content
    ...ReportLink_Content
    ...KeyFigures_Content
  }
  ...TrendingContent_1jQ2Cn
}

fragment ForumPosts on ForumPost {
  text
  likesCount
  url
  author
  postedAt
  authorImgUrl
}

fragment KeyFigures_Content on Content {
  __isContent: __typename
  companies {
    defaultInstrument {
      estimateData {
        modelType
        reportingCurrency
      }
      snapshot {
        transaction {
          date
          actualized {
            year
            quarter
            revenue
            revenueGrowth
            ebitAdjusted
            ebitReported
            ebitda
            enterpriseValue
            epsAdjusted
            dividend
            dividendYield
            sharePrice
            nav
            navPerShare
            opexOfNav
            quarterlySharePrice
          }
          estimates {
            year
            quarter
            revenue
            revenueGrowth
            ebitAdjusted
            ebitReported
            ebitda
            enterpriseValue
            epsAdjusted
            dividend
            dividendYield
            sharePrice
            nav
            navPerShare
            opexOfNav
            quarterlySharePrice
          }
        }
      }
      id
    }
    id
  }
}

fragment PriceAndRecommendation_Content on Content {
  __isContent: __typename
  createdAt
  companies {
    name
    pageUrl
    defaultInstrument {
      priceData {
        tradeCurrency
      }
      snapshot {
        priceData {
          date
          lastPrice
          tradeCurrency
        }
        transaction {
          date
          recommendation
          targetPrice
        }
        prevTransaction {
          recommendation
        }
      }
      id
    }
    id
  }
}

fragment PublishingDetails on Content {
  __isContent: __typename
  createdAt
  publishers {
    name
    imgUrl
  }
  authors {
    __typename
    id
    name
    slug
    imgUrl
    jobTitle
  }
  ... on Video {
    liveTime
  }
  ... on Webcast {
    liveTime
  }
}

fragment Reactions on Content {
  __isContent: __typename
  id
  reactionGroups {
    reactionType
    reactionsCount
    viewerReacted
  }
}

fragment ReportLink_Content on Content {
  __isContent: __typename
  type
  isPremium
  ... on CompanyReport {
    reportUrl
  }
  ... on ThirdPartyCompanyReport {
    reportUrl
  }
  ... on StockExchangeRelease {
    reportUrl
  }
}

fragment TrendingContent_1jQ2Cn on Query {
  trendingContent(type: ARTICLE) {
    __typename
    id
    title
    lang
    pageUrl
    createdAt
    type
    imgUrl
    companies {
      squareLogoUrl
      name
      id
    }
    authors {
      __typename
      imgUrl
      id
    }
    publishers {
      imgUrl
    }
  }
}


dagens-aktienyheder-2503-2026-danish-aerospace-company-og-pharma-equity-group

__typename

title

isPremium

lang

htmlBody

summary

companies

createdAt

publishers

authors

reactionGroups

pageUrl

translations

imgUrl

description

Equity Research Assistant

Victor Skriver

Pharma Equity Group develops medicines for the treatment of serious and life-threatening inflammatory diseases for which there is currently no adequate treatment. The Company uses repositioning of existing medicines and takes drug candidates to a clinical Phase III stage, after which they are handed over to a strategic partner who will complete the development of the products and bring them to market, either independently or in collaboration with the Company.

Pharma Equity Group

Danish Aerospace Company is a supplier of products for the defense- and space industry, with a patented product portfolio, which mainly includes exercise equipment, biomedical equipment, health monitoring and water recovery units. Customers include, among others, international space organizations and private companies. DAC, which is located in Odense, has sent more than 3,5 tons of equipment into space.

Danish Aerospace Company

Dagens aktienyheder 25/03-2026: Danish Aerospace Company og Pharma Equity Group

I forbindelse med Danish Aerospace Company&#x2019;s (DAC) igangv&#xe6;rende fuldt garanterede fortegningsemission med et bruttoprovenu p&#xe5; DKK 24,7 mio. har vi udarbejdet en investeringscase. Vores investeringscase d&#xe6;kker de v&#xe6;sentligste investeringsgrunde, risici og v&#xe6;rdians&#xe6;ttelsesperspektiver. De centrale investeringsgrunde omfatter den forventede kraftige v&#xe6;kst i bemandede rummissioner drevet af geopolitisk rivalisering og privatisering af rumstationer, DAC&apos;s n&#xe6;sten-monopolstilling med en opdateret produktportef&#xf8;lje og st&#xe6;rk &quot;flight heritage&quot; siden 1989, at forventningerne er godt st&#xf8;ttet af kraftigt &#xf8;get offentlig og privat finansiering samt optionaliteten i dual-use-strategien, hvor DAC sigter mod at tage eksisterende rumteknologi ned p&#xe5; jorden og &#xe5;bne nye markeder i forsvarssegmentet. De v&#xe6;sentligste risici omfatter, at mange projekter fortsat er afh&#xe6;ngige af fuld finansiering, samt at anskaffelse og salg til milit&#xe6;ret er en langvarig og kompleks proces, der kan tage 3-7 &#xe5;r og kr&#xe6;ver specialiseret salgsviden. L&#xe6;s hele investeringscasen her: <a href="https://www.inderes.dk/research/danish-aerospace-company-investment-case-rumkaplob-version-20-skudt-i-gang">https://www.inderes.dk/research/danish-aerospace-company-investment-case-rumkaplob-version-20-skudt-i-gang</a>
Pharma Equity Group (PEG) forventes at offentligg&#xf8;re sit &#xe5;rsregnskab for 2025 i dag. I forl&#xe6;ngelse heraf inviteres der til en gennemgang af regnskabet med selskabets ledelse, som ogs&#xe5; vil besvare sp&#xf8;rgsm&#xe5;l fra publikum kl. 14:00. Tilmelding her: <a href="https://www.inderes.dk/videos/pharma-equity-group-praesentation-af-arsregnskabet-for-2025">https://www.inderes.dk/videos/pharma-equity-group-praesentation-af-arsregnskabet-for-2025</a>
Disclaimer: HC Andersen Capital modtager betaling fra de n&#xe6;vnte selskaber for en Digital IR abonnementsaftale. /Victor Skriver d. 25/03-2026 kl. 08:50.

HC Andersen Capital

<ul><li>Danish Aerospace Company gennemfører en fuldt garanteret fortegningsemission med et bruttoprovenu på DKK 24,7 mio., understøttet af forventet vækst i bemandede rummissioner og en stærk produktportefølje.</li><li>Væsentlige risici for DAC inkluderer afhængighed af fuld projektfinansiering og komplekse salgsprocesser til militæret, der kan tage 3-7 år.</li><li>Pharma Equity Group forventes at offentliggøre sit årsregnskab for 2025 i dag, efterfulgt af en præsentation og Q&A-session med ledelsen kl. 14:00.</li><li>HC Andersen Capital modtager betaling fra de nævnte selskaber for en Digital IR abonnementsaftale.</li></ul>Dette indhold er genereret af AI. Du kan give feedback om det på Inderes <a href="https://forum.inderes.com/t/inderes-fi-sisallon-kehitysideat/71/last">forum</a>.

Faron Pharmaceuticals

Herantis Pharma

Mendus

Probabilities of success in drug development

Financial Key Ratios: EV/EBIT, EV/EBITA, EV/EBITDA, and EV/Sales

Nordea Bank

Nordea shareholder? It’s easier than ever to attend the AGM with a new digital set-up

Return on capital (ROE, ROI, ROIC, RONIC)

Balance sheet, debt leverage and risks

Dagens aktienyheder 25/03-2026: Danish Aerospace Company og Pharma Equity Group

Summary

Stay up to date